FI120397B - Nya sulfonamider - Google Patents

Nya sulfonamider Download PDF

Info

Publication number
FI120397B
FI120397B FI972628A FI972628A FI120397B FI 120397 B FI120397 B FI 120397B FI 972628 A FI972628 A FI 972628A FI 972628 A FI972628 A FI 972628A FI 120397 B FI120397 B FI 120397B
Authority
FI
Finland
Prior art keywords
methoxy
phenoxy
pyridin
pyrimidin
tetrazol
Prior art date
Application number
FI972628A
Other languages
English (en)
Finnish (fi)
Other versions
FI972628A0 (sv
FI972628L (sv
Inventor
Werner Neidhart
Henri Ramuz
Volker Breu
Jean-Marie Cassal
Martine Clozel
Georges Hirth
Bernd-Michael Loeffler
Marcel Mueller
Kaspar Burri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of FI972628A0 publication Critical patent/FI972628A0/sv
Publication of FI972628L publication Critical patent/FI972628L/sv
Application granted granted Critical
Publication of FI120397B publication Critical patent/FI120397B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Bipolar Transistors (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Lubricants (AREA)
  • Steroid Compounds (AREA)
  • Surgical Instruments (AREA)

Claims (10)

1. Föreningar med formeln (1} r2 R1S02MH R4 Rs y—(i R3 R8 R7 5 där R1 är fenyl eller fenyl, som är substituerad med halogen, Ci_7-alkyl, Ci_7-alkoxi, Ci_7-alkylendi-oxi, karboxyl eller trifluormetyl; eller hetero-cyklyl, som är mono- eller bicykliska, 5- och 6-10 ledade heterocykler, som har syre, kväve eller svavel som heteroatom; R2 är tetrazolyl, Ci-7-alkyl-substituerad tetrazo- lyl, cyan, karboxi, Ci-7-alkoxikarbonyl, hydroxi-metyl, formyl, karbamoyl, tiokarbamoyl, amidino 15 eller hydroxiamidino; R3 är en rest -0- (CRaRb)n~OR9; R4 - R8 är väte, Ci-7-alkoxi eller halogen; R9 är väte, bensyl, bensyl, som i fenylringen är substituerad med halogen, Ci_7-alkyl, Ci-7-alkoxi, 20 Ci-7-alkylendioxi, karboxyl eller trif luormetyl ; eller en rest -CiONHR10; R10 är Ci-7-alkyl, fenyl eller fenyl, som är substi tuerad med halogen, Ci-7-alkyl, Ci_7-alkoxi, Ci_7-alkylendioxi, karboxyl eller trifluormetyl; el-25 ler pyridyl eller pyridyl, som är substituerad med 1 eller 2 Ci-7-alkylgrupper; Ra och Rb är väte eller Ci_7-alkyl; n är 2, 3 eller 4; och A och B är CH; eller den ena av symbolerna A eller B är 30 kväve och den andra är CH; eller R2 är väte och den ena av symbolerna A eller B är N-oxid (N->0) och den andra är CH, och farma- ceutiskt användbara salter av föreningarna med formeln I.
2. Föreningar enligt patentkrav 1, känneteck-nade av att A och B är CH. 5
3. Föreningar enligt patentkrav 1, känneteck- nade av att den ena av symbolerna A eller B är kväve.
4. Föreningar enligt patentkrav 1, känneteck-n a d e av att den ena av symbolerna A är kväve och B är CH. 10
5. Föreningar enligt nagot av patentkraven 1-4, kännetecknade av att R2 är en tetrazolylrest.
6. Föreningar enligt nagot av patentkraven 1-5, kännetecknade av att R1 är fenyl- eller pyridylrest, som är monosubstituerad med Ci-7-alkyl, R3 är -0(CH2)nOH, -
15 O (CH2) n0-bensyl eller -O (CH2) nOC (O) NHR10 och n är 2.
7. Föreningar enligt nagot av patentkraven 1-6, kännetecknade av att R4 är Cx-7-alkoxi och R5 - R8 är väte; eller R2 är halogen, R7 är Cx-7-alkoxi och R5, R6 och R8 är väte. 20
8. Föreningar enligt nagot av patentkraven 1-7, 5-metyl-pyridin-2-sulfonsyra 6~(2-hydroxietoxi)-5-(2-metoxi-fenoxi}-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-py-rimidin-4-ylamid, 5-isopropyl-pyridin-2-sulfonsyra 6-(2-hydroxietoxi)- 25 5-(2-metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)- pyrimidin-4-ylamid, 4-tert-butyl-N-[6-(2-hydroxietoxi)-5-(2-metoxi-fen-oxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-bensensulfonamid, 30 2-[6-(4-tert-butyl-fenylsulfonylamino)-5-(2-met- oxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxi]-etyl pyridin-2-ylkarbamat, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-bensensulfon- 35 amid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4~yl]-4-metyl-ben-sensulfonamid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(2-1H-5 tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-metoxi-ben-sensulfonamid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(2 — 1H— tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-metylsulfa-nyl-bensensulfonamid, 10 1,3-bensodioxol-5-sulfonsyra 6-(2-hydroxietoxi)-5- (2-metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-py-rimidin-4-ylamid, N-[6~(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(2 — 1H— tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimetoxi-15 bensensulfonamid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(2-1H-tetrazol-5-yl-pyridin~4-yl)-pyrimidin-4-yl]-2,5-dimetoxi-bensensulfonamid, pyridin-3-sulfonsyra 6-(2-hydroxietoxi)-5-(2-meto-20 xi-fenoxi)-2-(2-lH-tetrazol-5-yl~pyridin-4-yl)-pyrimidin- 4-ylamid, 4- tert-butyl-N-[5-(2-klor-5-metoxi-fenoxi)-6-(2-hydroxietoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl)-bensensulfonamid, 25 1,3-bensodioxol-5-sulfonsyra [5-(2-klor-5-metoxi- fenoxi)-6-(2-hydroxietoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-amid, 5- isopropyl-pyridin-2-sulfonsyra [5-(2-klor-5-met-oxi-fenoxi)-6-(2-hydroxietoxi)-2-(2-lH-tetrazol-5-yl-pyri- 30 din-4-yl)-pyrimidin-4-yl]-amid, 4-tert-butyl-N-[6-(2-hydroxietoxi)-5-(2-metoxi-fe-noxi)-2-[6-(lH-tetrazol-5-yl-pyridin-4-yl)]-pyrimidin-4-yl]-bensensulfonamid, 2-[5-(2-metoxi-fenoxi)-6-fenylsulfonylamino-2-(2-35 lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxi]-etylpy- ridin-2-ylkarbamat, 2-[5- (2-metoxi-fenoxi)-6-(4-metyl-fenylsulfonyl-amino)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxi]-etylpyridin-2-ylkarbamat, 2-[5-(2-metoxi-fenoxi)-6-(4-metyl-fenylsulfonyl-5 amino)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4- yloxi]-etyl 1,3-bensodioxol-5-ylkarbamat, 2-[5-(2-metoxi-fenoxi)-6-(4-metoxi-fenylsulfonyl-amino)-2-(2-lH-tetrazol-5-yl-pyridin-2-yl)-pyrimidin-4-yl-oxi]-etyl pyridin-2-ylkarbamat, 10 2-(5-(2-metoxi-fenoxi)-6-(4-metoxi-fenylsulfonyl- amino)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxi]-etyl 1,3-bensodioxol-5ylkarbamat, 2-[5-(2-metoxi-fenoxi)-6-(4-metylsulfanyl-fenyl-sulfonylamino)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimi-15 din-4-yloxi]-etyl pyridin-2-ylkarbamat, 2-[6-(1,3-bensdioxol-5-ylsulfonylamino)-5-(2-metoxi-fenoxi) -2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin- 4-yloxi]-etyl pyridin-2-ylkarbamat, 2-[6-(1,3-bensdioxol~5-ylsulfonylamino)-5-(2-meto-20 xi-fenoxi)-2-(2-lH-tetrazol~5~yl-pyridin-4-yl)-pyrimidin- 4-yloxi]-etyl 1,3-bensodioxol-5-ylkarbamat, 2-[6-(3,4-dimetoxi-fenylsulfonylamino)-5-(2-metoxi-fenoxi) -2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin- 4-yloxi]-etyl pyridin-2-ylkarbamat, 25 2-[5-(2-metoxi-fenoxi)-6-(2,5-dimetoxi-fenylsulfo- nylamino)-2-(2-lH-tetrazol-5-yl-pyrxdxn-4-yl)-pyrimidin-2-yloxi]-etyl pyridxn-2-ylkarbamat, 2-[5-(2-metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyri-din-4-yl)-6-pyridin-3-ylsulfonylamino-pyrimidin-4-yloxi]-30 etyl pyridin-2-ylkarbamat, 2-[5-(2-metoxi-fenoxi)-6-pyrxdin-3-ylsulfonylami-no-2-(2-lH-tetrazol-5-yl-pyrxdin-4-yl)-pyrimidin-4-yloxi]-etyl 1,3-bensodioxol-5-ylkarbamat, 2-[5-(2-metoxi-fenoxi)-6-(5-metyl-pyridin-2-ylsul-35 fonylamino)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin- 4-yloxi]-etyl pyrxdin-2-ylkarbamat, 2-[6-(5-isopropyl-pyridin-2-ylsulfonylamino)-5-(2-metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimi-din-4-yloxi]-etyl pyridin-2-ylkarbamat, 2-[6-(5-isopropyl-pyridin-2-ylsulfonylamino)-5-(2-5 metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimi- din-4-yloxi] -etyl 1,3-bensodioxol-5-ylkarbamat, 2-[6~(5-tert-butyl-fenylsulfonylamino)-5-(2-klor- 5-metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyri-midin-4-yloxi]-etyl pyridin-2-ylkarbamat, 10 2-[6-(1,3-bensodioxol-5-ylsulfonylamino)-5-(2-klor- 5-metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyri-midin-4-yloxi]-etyl pyridin-2-ylkarbamat, 2-[5-(2-klor-5-metoxi-fenoxi)-6-(5-isopropyl-pyri-din-2-ylsulfonylamino]-2-(2-lH-tetrazol-5-yl-pyridin-2-yl)-15 pyrimidin-4-yloxi]-etyl pyridin-2-ylkarbamat, 2-[6-{4-tert-butyl-fenylsulfonylamino)-5-(2-metoxi-fenoxi) -2-(2-lH-tetrazol-5-yl-pyridin-2-yl)-pyrimidin- 4-yloxi]-etyl pyridin-2-ylkarbamat, N-(6-(2-bensyloxi-etoxi)-5-(2-metoxi-fenoxi)-2-(2-20 lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-tert-bu- tyl-bensensulfonamid, 5-metyl-pyridin-2-sulfonsyra [6- (2-bensyloxi-eto-xi)-5-(2-metoxi-fenoxi)-2-(2-lH-tetrazol~5~yl~pyridin~4~ yl)]-amid, 25 5-isopropyl-pyridin-2-sulfonsyra [6-(2-bensyloxi- etoxi) -5-(2-metoxi-fenoxi)-2-[2-(lH-tetrazol-5-yl-pyridin- 4-yl)]-pyrimidin-4-yl]-amid, 4-tert-butyl-N-(2-[2-(l-etyl-lH-tetrazol-5-yl)py-ridin-4-yl]-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimi-30 din-4-yl]-bensensulfonamid, 4-tert-butyl-N-(2-(3-cyan-fenyl)-6-(2-hydroxietoxi) -5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-bensensulfonamid, 4-tert-butyl-N-(6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi) -2-(3~lH~tetrazol-5-yl-fenyl)-pyrimidin-4-yl]-ben-35 sensulfonamid, 2-[6-(4-tert-butyl-fenylsulfonylamino)-5-(2-meto-xi-fenoxi) -2- (3-lH-tetrazol-5-yl-fenyl) -pyrimidin-4-yloxi] -etyl pyridin-2-ylkarbamat, N- [ 6- (2-bensyloxi-etoxi)-2-(3-cyan-fenyl)-5-(2-me-5 toxi-fenoxi)-pyrimidin-4-yl]-4-tert-butyl-bensensulfonamid, N-[6-(2-bensyloxi-etoxi)-5-(2~metoxi-fenoxi)-2- (3-lH-tetrazol-5-yl-fenyl)-pyrimidin-4-yl]-4-tert-butyl-ben-sensulfonamid, 4-tert-butyl-N-[2-(4-cyan-fenyl)-6-(2-hydroxieto-10 xi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl)-bensensulfonamid, 4-tert-butyl-N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(4-lH-tetrazol-5-yl-fenyl)-pyrimidin-4-yl]-bensensulfonamid, N-[6- (2-bensyloxi-etoxi)-2-(4-cyan-fenyl)-5-(2-15 metoxi-fenoxi)-pyrimidin-4-yl]-4-tert-butyl-bensensulfon- amid, N-[6-(2-bensyloxi-etoxi)-5-(2-metoxi-fenoxi)-2-(4-lH-tetrazol-5-yl-fenyl)-pyrimidin-4-yl]-4-tert-butyl-ben-sensulfonamid, 20 4-tert-butyl-N-[2-(2-cyan-pyridin-4-yl)-6-(2-hyd roxietoxi) -5- (2-metoxi-fenoxi) -pyrimidin-4-yl] -bensensulfonamid, N-[2- (2-cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-bensensulfonamid,
25 N-[2-(2-cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-5- (2-metoxi-fenoxi)-pyrimidin-4-yl]-4-metyl-bensensulfon-amid, N-(2-(2-cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-4-metoxi-bensensulfon-30 amid, N-[2-(2-cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-4-metylsulfanyl-bensen-sulfonamid, 1,3-bensodioxol-5-sulfonsyra 2-(2-cyan-pyridin-4-35 yl)-6- (2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4- ylamid, N-[2-(2-cyan-pyridin-4-yl}-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-3,4-dimetoxi-bensensul-fonamid, N-[2-(2-cyan-pyridin-4~yl)-6-(2-hydroxietoxi)-5-5 (2-metoxi-fenoxi)-pyrimidin-4-yl]-2,5-dimetoxi-bensensul- fonamid, pyridin-3-sulfonsyra 2-(2-cyan-pyridin~4~yl) -6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-ylamid, 5-metyl-pyridin-2-sulfonsyra 2-(2-cyan-pyridin-4-10 yl) -6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl- amid, 5-isopropyl-pyridin-2-sulfonsyra 2-(2-cyan-pyridin-4 —yl)-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-ylamid, 15 4-tert-butyl-N-[5-(2-klor-5-metoxi-fenoxi)-2-(2- cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-pyrimidin-4-yl]-ben-sensulfonamid, 1,3-bensodioxol~5-sulfonsyra 5- (2-klor-5-metoxi-fe-noxi)-2-(2-cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-pyrimi-20 din-4-ylamid, 5-isopropyl-pyridin-2"Sulfonsyra 5-(2-klor-5-meto-xi-fenoxi)-2-(2-cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-py-rimidin-4-ylamid, 4-tert-butyl-N-[2-(6-cyan-pyridin-2-yl)-6-(2-hyd-25 roxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-bensensul- fonamid, N-[6- (2-bensyloxi-etoxi)-2-(2-cyan-pyrdin-4-yl)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-4-tert-butyl-bensensul-fonamid, 30 5-isopropyl-pyridin-2-sulfonsyra-N-[6-(2-bensyl- oxi-etoxi)-2-(2-cyan-pyrdin-4-yl)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-amid, 4-tert-butyl-N-[2-[2-(amino-imino-metyl)-pyridin- 4-yl]-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-35 yl]-bensensulfonamid, 4- tert-butyl-N-[2-[2-(hydroxiamino-imino-metyl) -pyridin-4-yl]-6-(2-hydroxietoxi)-5-{2-metoxi-fenoxi)-pyri-midin-4~yl] -bensensulfonamid, etyl N- [4- (4-tert-butyl-fenylsulfonylamino)-6-(2-5 hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-2-yl]-pyridin- 2-karboxylat, N-[4-(4-tert-butyl-fenylsulfonylamino)-6-(2-hydroxietoxi) -5-(2-metoxi-fenoxi)-pyrimidin-2-yl]-pyridin-2-karboxylsyra,
10 N-[4-(4-tert-butyl-fenylsulfonylamino)-6-(2-hydro xietoxi )-5-(2-metoxi-fenoxi)-pyrimidin-2-yl]-pyridin 1-oxid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2- (1-oxi-pyridin-4-yl)-pyrimidin-4-yl]-bensensulfonamid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(1-oxi-15 pyridin-4-yl)-pyrimidin-4-yl]-4-metyl-bensensulfonamid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(1-oxi-pyridin-4-yl)-pyrimidin-4-yl]-4-metoxi-bensensulfonamid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(1-oxi-pyridin-4-yl)-pyrimidin-4-yl]-4-metylsulfanyl-20 bensensulfonamid, 1,3-bensidioxol-5-sulfonsyra 6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(l-oxi-pyridin-4-yl)-pyrimidin-4-yl-amid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(1-oxi-25 pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimetoxi-bensensulfon amid, N-[6- (2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(1-oxi-pyridin-4-yl)-pyrimidin-4-yl]-2,5-dimetoxi-bensensulfon-amid, 30 pyridin-3-sulfonsyra 6- (2-hydroxietoxi)-5-(2-meto- xi-fenoxi)-2-(l-oxi-pyridin-4-yl)-pyrimidin-4-yl-amid, 5- metyl-pyridin-2-sulfonsyra 6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(l-oxi-pyridin-4-yl)-pyrimidin-4-yl-amid, 5-isopropyl-pyridin-2-sulfonsyra 6-(2-hydroxieto-xi)-5-(2-metoxi-fenoxi)-2-(l-oxi-pyridin-4-yl)-pyrimidin-4-yl-amid, 4-tert-butyl-N-[5-(2~klor-5-metoxi-fenoxi)-6-(2-5 hydroxietoxi)-2-(l-oxi-pyridin-4-yl)-pyrimidin-4-yl]-ben-sensulfonamid, 1,3-bensodioxol-4-sulfonsyra 5-(2-klor-5-metoxi~ fenoxi)-6-(2-hydroxietoxi)-2-{l-oxi-pyridin~4-yl)-pyrimi-din-4-ylamid, 10 5~isopropyl-pyridin-4“Sulfonsyra 5-(2-klor-5-meto- xi-fenoxi)-6-(2-hydroxietoxi)-2-(l-oxi-pyridin-4-yl)-pyri-midin-4-ylamid, 2-[4~(4-tert-butyl-fenylsulfonylamino)-6-(2-hydroxietoxi) -5-(2-metoxi-fenoxi}-pyrimidin-2-yl]-pyridin 1-oxid. 15
9. Farmaceutiska preparat, speciellt sädana, som är avsedda för att behandla störningar, som hänför sig till endotelinaktiviteter, speciellt blodcirkulationsstör-ningar, sasom hypertension, ischemi, vasospasm och angina pectoris, kännetecknade av att de innehäller en fö-20 rening enligt nagot av patentkraven 1-8 och konventio-nella bärarmaterial och adjuvanter.
10. Användning av föreningar enligt nagot av patentkraven 1-8 som aktiva ingredienter vid framställning av rnedikament, som är avsedda för att behandla störningar, 25 som hänför sig till endotelinaktiviteter, speciellt blod-cirkulationsstörningar, sasom hypertension, ischemi, vasospasm och angina pectoris.
FI972628A 1994-12-20 1997-06-18 Nya sulfonamider FI120397B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CH383794 1994-12-20
CH383794 1994-12-20
CH241995 1995-08-24
CH241995 1995-08-24
EP9504843 1995-12-08
PCT/EP1995/004843 WO1996019459A1 (en) 1994-12-20 1995-12-08 Novel sulfonamides

Publications (3)

Publication Number Publication Date
FI972628A0 FI972628A0 (sv) 1997-06-18
FI972628L FI972628L (sv) 1997-06-18
FI120397B true FI120397B (sv) 2009-10-15

Family

ID=25690401

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972628A FI120397B (sv) 1994-12-20 1997-06-18 Nya sulfonamider

Country Status (25)

Country Link
US (1) US6004965A (sv)
EP (1) EP0799209B1 (sv)
JP (1) JP2989014B2 (sv)
KR (1) KR100445085B1 (sv)
CN (1) CN1098254C (sv)
AT (1) ATE246681T1 (sv)
AU (1) AU701767B2 (sv)
BR (1) BR9510104A (sv)
CA (1) CA2208018C (sv)
CY (1) CY2495B1 (sv)
CZ (1) CZ287916B6 (sv)
DE (1) DE69531457T2 (sv)
DK (1) DK0799209T3 (sv)
ES (1) ES2203649T3 (sv)
FI (1) FI120397B (sv)
HU (1) HU228619B1 (sv)
IL (1) IL116385A (sv)
MA (1) MA23744A1 (sv)
MY (1) MY131126A (sv)
NO (1) NO316645B1 (sv)
NZ (1) NZ297797A (sv)
PT (1) PT799209E (sv)
SA (1) SA95160421B1 (sv)
TW (1) TW313568B (sv)
WO (1) WO1996019459A1 (sv)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2615357T3 (es) 1996-12-06 2017-06-06 Amgen Inc. Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1
DE69824090T2 (de) 1997-08-19 2005-07-07 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von 2,5-disubstituierter Pyridine
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
DK0979822T3 (da) * 1998-08-10 2006-03-27 Hoffmann La Roche Fremgangsmåde til fremstilling af 2-carbamoyl-pyridiner
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
US6417360B1 (en) 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
ZA200002318B (en) * 1999-05-22 2000-11-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition.
AU747596B2 (en) * 1999-05-22 2002-05-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
CA2361402C (en) 1999-09-03 2009-05-12 Actelion Pharmaceuticals Ltd Bis-sulfonamides
AU3536701A (en) * 1999-12-22 2001-07-03 Actelion Pharmaceuticals Ltd Butyne diol derivatives
WO2001081338A1 (en) * 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
PT1345920E (pt) 2000-12-18 2006-08-31 Actelion Pharmaceuticals Ltd Novas sulfonamidas e sua utilizacao como antagonistas dos receptores de endotelina
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
AU2003285321B2 (en) * 2002-12-02 2010-04-08 Actelion Pharmaceuticals Ltd Pyrimidine-sulfamides and their use as endothelian receptor antagonist
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
RS52625B (sr) 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2007529459A (ja) 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト 治療に置けるレニン阻害剤の使用
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP2049517B1 (en) 2006-07-20 2013-11-27 Novartis AG Amino-piperidine derivatives as cetp inhibitors
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
CN101855241B (zh) 2006-12-08 2013-11-06 莱克康制药公司 针对angptl3的单克隆抗体
EP3000487B8 (en) 2007-02-19 2022-06-15 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
FR2921062A1 (fr) * 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
SI2207775T1 (sl) 2007-11-05 2012-05-31 Novartis Ag benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza
CN101878199B (zh) 2007-12-03 2013-09-18 诺瓦提斯公司 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物
JP5659224B2 (ja) 2009-05-15 2015-01-28 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリールピリジン
US8455522B2 (en) 2009-05-15 2013-06-04 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
MX2011012628A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
ES2582395T3 (es) 2009-05-28 2016-09-12 Novartis Ag Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CN102712589B (zh) 2009-11-17 2015-05-13 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基-吡啶衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN102666535B (zh) 2009-11-30 2015-02-25 诺华股份有限公司 作为醛固酮合酶抑制剂的咪唑衍生物
US8858964B2 (en) 2010-04-15 2014-10-14 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-N-acetylglucosamine nanofibers
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
BR112013012858B1 (pt) 2010-11-24 2021-12-07 Lexicon Pharmaceuticals, Inc Anticorpo monoclonal que se liga a pectinacetilesterase de notum, composição farmacêutica, molécula de ácido nucleico, célula hospedeira e método para produzir o dito anticorpo
US20140127310A1 (en) 2011-04-15 2014-05-08 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
JP6295277B2 (ja) 2013-02-14 2018-03-14 ノバルティス アーゲー Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
WO2016116842A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
TWI835843B (zh) 2018-10-03 2024-03-21 瑞士商亨斯邁紡織染化（瑞士）有限公司 新的經吡啶及經嘧啶取代之三ｕｖ吸收劑
CA3197265A1 (en) 2020-11-05 2022-05-12 Timo Rager A stable crystalline hydrate of clazosentan disodium salt
WO2023111299A1 (en) 2021-12-17 2023-06-22 Idorsia Pharmaceuticals Ltd Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same
US20250228835A1 (en) * 2024-01-12 2025-07-17 Rectify Pharmaceuticals, Inc. Pyridinyloxypyridines and related compounds and their use in treating medical conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270116B (sv) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (sv) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
NO316645B1 (no) 2004-03-22
WO1996019459A1 (en) 1996-06-27
NO972538D0 (no) 1997-06-04
PT799209E (pt) 2003-12-31
MY131126A (en) 2007-07-31
AU4304196A (en) 1996-07-10
DE69531457D1 (en) 2003-09-11
CN1098254C (zh) 2003-01-08
HU228619B1 (en) 2013-04-29
CZ287916B6 (cs) 2001-03-14
FI972628A0 (sv) 1997-06-18
NZ297797A (en) 1999-10-28
SA95160421B1 (ar) 2006-05-01
MA23744A1 (fr) 1996-07-01
IL116385A (en) 2000-07-16
HK1001973A1 (en) 1998-07-24
CZ187497A3 (en) 1997-10-15
DK0799209T3 (da) 2003-11-24
ES2203649T3 (es) 2004-04-16
BR9510104A (pt) 1997-11-25
CN1170407A (zh) 1998-01-14
DE69531457T2 (de) 2004-06-24
CA2208018A1 (en) 1996-06-27
JPH10509182A (ja) 1998-09-08
EP0799209A1 (en) 1997-10-08
MX9704587A (es) 1998-07-31
FI972628L (sv) 1997-06-18
KR100445085B1 (ko) 2004-10-14
CY2495B1 (en) 2005-09-02
CA2208018C (en) 2007-03-27
IL116385A0 (en) 1996-03-31
EP0799209B1 (en) 2003-08-06
US6004965A (en) 1999-12-21
JP2989014B2 (ja) 1999-12-13
ATE246681T1 (de) 2003-08-15
AU701767B2 (en) 1999-02-04
TW313568B (sv) 1997-08-21
NO972538L (no) 1997-06-04
HUT77884A (hu) 1998-09-28

Similar Documents

Publication Publication Date Title
FI120397B (sv) Nya sulfonamider
FI112944B (sv) Förfarande för framställning av nya terapeutiskt användbara sulfonylaminopyrimidinderivat
KR100819668B1 (ko) 신규한 피리미딘-설퍼아마이드
KR100478797B1 (ko) 엔도텔린 수용체 길항제로서의 4-(헤테로사이클릴설폰아미도)-6-메톡시-5-(2-메톡시페녹시)-2-페닐- 또는 -피리딜-피리미딘
WO2001017976A1 (en) Bis-sulfonamides
US7091201B2 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
AU2002212171A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
CZ289920B6 (cs) Derivát sulfonamidu, způsob jeho přípravy, farmaceutický prostředek, který ho obsahuje a meziprodukt pro jeho přípravu
WO2001081335A1 (en) Pyrimidine-sulfonamides having endothelin-antagonist activity
JPH09110840A (ja) 新規なスルホニルアミノピリミジン類
RU2151767C1 (ru) Сульфонамиды и фармацевтическая композиция
WO2002083650A1 (en) Novel sulfonylamino-pyrimidines
NO327220B1 (no) Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser
MXPA97004587A (es) Sulfonamidas novedosas
PL185692B1 (pl) Nowe sulfonamidy, sposób ich wytwarzania oraz zawierające je preparaty farmaceutyczne
HK1001973B (en) Sulfonamides
EP1322624B1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120397

Country of ref document: FI

MA Patent expired